Abstract Percutaneous coronary intervention (PCI) is one of the most common medical procedures performed for treatment of coronary artery disease. Antiplatelet medications as adjunctive therapy for PCI are used routinely, with indications for specific agents or their combinations varying depending on the clinical scenario. While the cost effectiveness of well-established agents has been extensively studied, newer drugs have not been evaluated as thoroughly. In addition, the clinical application of some antiplatelet drugs has recently changed, thus making older studies of cost effectiveness less applicable to the current landscape of clinical practice. This article reviews costeffectiveness considerations of antiplatelet therapies in the treatment of coronary artery disease in patients undergoing PCI. Aspirin, P2Y12 inhibitors including clopidogrel and the newer agents prasugrel and ticagrelor, as well as glycoprotein (GP) IIb/IIIa inhibitors, are discussed. Overall, the use of dual antiplatelet therapy with aspirin and a P2Y12 inhibitor in patients undergoing PCI improves ischaemic outcomes and appears to be cost effective. The few available studies suggest that the recently approved medications prasugrel and ticagrelor are cost-effective alternatives to clopidogrel. However, no direct comparison between these two newer agents is available. The indications for GP IIb/IIIa inhibitors have changed in the current PCI era, and there is a paucity of cost-effectiveness data for their use in contemporary care.
• Antiplatelet therapy for PCI appears to be costeffective.
• A critical component of cost-effectiveness analysis is choosing the most clinically relevant comparator. By its nature, cost-effectiveness analysis offers incremental comparison between a new therapy or service and a previous standard. If an inappropriate standard is chosen, a new therapy may incorrectly seem to offer good value.
• With the evolution of clinical practice, new studies are required to adequately evaluate new therapies and confirm the relevance of older studies.
Introduction
Coronary artery disease is exceedingly common and expensive [1] . In addition to medical therapy, percutaneous coronary intervention (PCI), including balloon angioplasty, stent placement and adjunctive procedures such as thrombectomy and atherectomy, is frequently utilized in the treatment of symptomatic coronary artery disease. PCI is the treatment of choice for two major subsets of coronary artery disease: high-risk acute coronary syndromes (ACS), including ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI) and unstable angina (UA), and in conjunction with optimized guideline-directed medical therapy for stable, symptomatic ischaemic heart disease [2, 3] . Coronary angioplasty is achieved by inflating specially designed balloons at super-atmospheric pressures to relieve the stenosis at the site of the lesion. This results in obligatory injury to the vessel wall structures, which exposes the thrombogenic subendothelial matrix and collagen to platelets, which may initiate platelet adhesion and activation, which in turn promotes thrombus formation [4] . Bare metal stent (BMS) implantation reduces the natural tendency for vessel recoil after balloon angioplasty, thus promoting long-standing vessel patency. However, tissue healing after said injury leads to scar tissue formation and stent restenosis. Drug-eluting stents (DES) reduce this reaction and thus limit scar tissue formation and restenosis, but increase the time for re-epithelization of the stent struts, thus prolonging the existence of and exposure to a potentially thrombogenic milieu [5] . This prolonged exposure can lead to both early and delayed ([1 year) stent thrombosis, manifesting as ACS and myocardial infarction.
Several pharmacological strategies have been utilized to decrease the risk of thrombotic events. First, periprocedural anticoagulation with either unfractionated or low-molecular-weight heparin or bivalirudin is routinely used. In addition, as platelets are central to the initiation, propagation and maintenance of PCI-related thrombus, several antiplatelet regimens have been employed. The anti-platelet agents can be categorized into aspirin, thienopyridine (clopidogrel and prasugrel) and non-thienopyridine (ticagrelor) adenosine diphosphate (ADP) P2Y12 receptor inhibitors, and glycoprotein (GP) IIb/IIIa inhibitors. As a group, these agents have been shown to decrease ischaemic events in patients undergoing PCI, but their use varies depending on the clinical setting [6] [7] [8] .
Current recommendations for antiplatelet therapy in patients undergoing PCI differ somewhat, depending on the indication for PCI, as well as the type of stent implanted (BMS vs DES). The indications can be generalized to ACS (STEMI and NSTEMI/UA), in which PCI generally portends a survival benefit, and non-ACS (stable angina), where PCI is a symptomatic treatment [2] . Aspirin is recommended for all manifest coronary disease and should be initiated before PCI and indefinitely thereafter. A P2Y12 inhibitor loading dose is recommended at the time of or prior to ACS PCI, while clopidogrel alone is recommended for non-ACS PCI. The recommended duration of dual antiplatelet therapy (DAPT) varies: in the setting of PCI for ACS, 12 months of DAPT is currently recommended, regardless of the type of stent implanted, while for PCI in the non-ACS setting, at least 12 months of DAPT is recommended for patients receiving DES and at least 1 month and up to 12 months for patients receiving BMS. Earlier discontinuation of DAPT in patients at high risk of bleeding is reasonable if this risk exceeds the perceived benefit.
The recommendations for use of GP IIb/IIIa inhibitors have been updated recently [2, 9] . The benefit of these intravenous platelet inhibitors in the setting of PCI has been demonstrated in multiple studies. However, current management strategies-in particular, adoption of early intervention, treatment of patients with P2Y12 inhibitors and increasing use of bivalirudin as an anticoagulanthave diminished their applicability to contemporary practice, largely owing to the excess bleeding that accompanies their use when they are paired with aspirin and a P2Y12 inhibitor [10, 11] . Nonetheless, GP IIb/IIIa inhibitors are considered reasonable at the time of PCI for patients not pretreated with a P2Y12 inhibitor in both the ACS (class IIa) and non-ACS (class IIa and IIb) settings [2, 9] . Furthermore, in patients exhibiting high-risk features, such as diabetics with elevated biomarkers and dynamic electrocardiographic changes, administration of GP IIb/IIIa inhibitors prior to or at the time of PCI has a class I indication as part of DAPT in UA/NSTEMI [10] . It is worth noting that routine administration of GP IIb/IIIa inhibitors prior to primary PCI for STEMI (i.e. facilitated PCI) is not beneficial and may be harmful [2] . The intravenous P2Y12 blocker cangrelor, which, like GP IIb/ IIIa inhibitors, has been used intra-procedurally, has recently been approved by the US Food and Drug Administration and is likely to be incorporated into practice, especially in patients with ACS [12] .
Cost Effectiveness Based on Models and Clinical Trials
Cost-effectiveness analysis (CEA) always involves comparison of a new therapy with a previous standard or control [13] . Effectiveness is most commonly measured in life years or quality-adjusted life years (QALYs), which permits comparison of CEAs across wide disciplines in medicine. The fundamental measure is the incremental cost effectiveness ratio (ICER), which is the ratio of the incremental cost of a new therapy compared with control, divided by the incremental cost. There are always assumptions involved in the calculation of both the measure of effectiveness and cost, and associated error. CEA may be developed entirely from models or from patientlevel data alongside clinical trials [14] . CEA from trials offers patient-level data, permitting assessment of stochastic error. However, virtually all CEA involves some element of modelling. The time horizon of CEA poses analytic challenges; it may be confined to a clinical trial period, a limited number of years or a lifetime. Lifetime assessment theoretically offers the best approach to making CEA comparable across disciplines. However, both CEAs from models and alongside clinical trials require assumptions about life expectancy, which may be difficult to evaluate. There will generally be uncertainty concerning the life expectancy of the control group, and, if there is a difference in survival at the end of the observed clinical trial data, the survival curves could continue to move apart, move in parallel or converge, offering varying results. The various sources of uncertainty can be assessed to some extent by sensitivity analysis, which is generally available in most published CEAs.
Aspirin
There is a paucity of studies illuminating the cost effectiveness of aspirin in the setting of PCI, for either the ACS or non-ACS indication. However, the clinical effectiveness of aspirin has been evaluated as a primary prevention agent and as a secondary prevention agent. The effectiveness of aspirin in primary prevention depends upon the patient risk profile, with higher-risk populations deriving most benefit. Additionally, there are gender-specific differences, with aspirin appearing to be effective in reducing the rate of myocardial infarction in high-risk men and stroke in highrisk women [15] . The role of aspirin in secondary prevention is well established in both men and women [16] . However, aspirin increases the risks of gastrointestinal bleeding and hemorrhagic stroke [17] . Several cost-effectiveness studies have been performed with aspirin (Table 1) . One study, using a Markov statetransition model with a base-case of a 45-year-old man with a 10-year coronary heart disease risk of 7.5 %, demonstrated that aspirin was dominant for primary prevention in this population [18] . The study was conducted from a third-party payer perspective and included only men. The duration of treatment was 10 years, with a lifetime event horizon. Aspirin increased the mean QALYs from 17.16 to 17.20 at a lower cost ($6,090 vs $6,694). Another Markov model-based European study examined the cost effectiveness of aspirin separately in men and women across ages and levels of risk [19] . Event rates were extrapolated from the Dutch population data, and a gender-specific meta-analysis was used to estimate the clinical effectiveness of aspirin in both genders. The ICER ranged from €34 for 65-year-old men with five times the baseline risk of cardiovascular disease (CVD) to €141,160 for 45-year-old men with twice the baseline risk. Similar risk-related variability was noted for women. The authors concluded that, using a threshold of €20,000, aspirin in primary prevention is cost effective for men with a 10-year CVD risk of 10 %, and for women with a 10-year CVD risk of 15 %. Similarly, Earnshaw et al. [20] showed that treatment with aspirin for primary prevention was less costly and more effective than no treatment in men older than 45 years of age with a 10-year risk of CHD greater than 10 %. For secondary prevention, Gaspoz et al. [21] , in a Coronary Heart Disease Policy Model-based study, found that increasing the use of aspirin from current levels to all eligible patients for 25 years would have an ICER of $11,000 per QALY gained.
The majority of patients undergoing PCI have a significant burden of coronary disease, and, in many cases, PCI is performed as treatment for an index or recurrent myocardial infarction. Therefore, these patients either fall into the secondary prevention category or are in the high-risk primary prevention group of patients. Indeed, in a recently published observational comparative effectiveness study of coronary revascularization strategies, the 4-year unadjusted mortality in the PCI cohort was 20.9 % [22] . Thus, despite the absence of direct evidence, it is probably reasonable to extrapolate the results of the primary and secondary prevention CEAs of aspirin to patients undergoing PCI.
Adenosine Diphosphate P2Y12 Receptor Inhibitors

Clopidogrel
The addition of P2Y12 inhibitors to aspirin has been shown to be beneficial in patients undergoing PCI and has formed the basis of DAPT [23] . Until recently, the thienopyridines clopidogrel and ticlopidine have been the two agents available for this purpose, with clopidogrel used predominantly because of haematological adverse reactions associated with use of ticlopidine [24] . In 2010, prasugrel became available for patients with ACS undergoing PCI, followed more recently by approval of the non-thienopyridine ticagrelor for the same indication [7, 8] . Of the four currently available P2Y12 inhibitors, clopidogrel has been the most extensively studied clinically, as well as from the cost-effectiveness perspective.
Several trials have evaluated the benefits of clopidogrel in varied clinical settings, most involving high-risk patient populations or patients presenting with ACS: CAPRIE [25] , CURE [6] , CREDO [26] , CLARITY TIMI-28 [27] , CHARISMA [28] and COMMIT [29] . These trials inform clinical decisions in patients with coronary artery disease in the acute setting as well as for secondary prevention. However, some but not all of these trials included and separately evaluated patients undergoing PCI. Economic considerations of clopidogrel as a secondary prevention agent have been reviewed previously [30, 31] .
The CURE trial showed beneficial effects of DAPT with aspirin plus clopidogrel compared with aspirin alone in the setting of ACS without ST elevation when initiated at the time of the index event and continued for an average duration of up to 1 year [6] . The trial's primary outcome-a composite of death from cardiovascular causes, nonfatal myocardial infarction or stroke-occurred in 9.3 % of patients in the clopidogrel group and in 11.4 % of patients in the placebo group (relative risk with clopidogrel vs placebo 0.80; 95 % CI 0.72-0.90; p \ 0.001) [6] . Additionally, PCI-CURE evaluated the effectiveness and cost-effectiveness of In all studies in Table 1 based on CURE and PCI-CURE, DAPT with aspirin and clopidogrel compared with aspirin alone was found to be well within the commonly quoted threshold for cost effectiveness (\$50,000). However, while studies based on the CURE trial elucidate the economic implications of DAPT in the setting of ACS, only the two studies based on the PCI-CURE trial are specifically relevant to the patient population undergoing PCI in this setting. Furthermore, because CURE and PCI-CURE included only patients with ACS without ST elevation, CEAs based on these trials are not directly relevant to the PCI population in other clinical settings, i.e. STelevation MI and stable coronary disease on DAPT.
The clinical benefit of adding clopidogrel to the background of fibrinolysis and aspirin in patients with STEMI was demonstrated in the CLARITY TIMI-28 trial [27] . In this trial, 3,491 patients within 12 h of onset of STEMI were randomly assigned to receive clopidogrel or placebo in addition to a fibrinolytic agent and aspirin. The primary efficacy endpoint was a composite of an occluded infarctrelated artery on angiography or death or recurrent myocardial infarction before angiography. The primary endpoint was reached in 21.7 % of patients in the placebo arm and in 15.0 % of those in the clopidogrel arm, representing 6.7 % absolute and 36 % relative risk reductions (95 % CI 24-47; p \ 0.001) [27] . A planned prospective analysis of patients who underwent PCI was reported in the PCI-CLARITY study [43] . During the 30-day study period, the incidence of cardiovascular death, MI or stroke was decreased in the clopidogrel arm compared with placebo (70 [7. 5 %] versus 112 [12. 0 %]; adjusted OR 0.59; 95 % CI 0.43-0.81; p = 0.001). The number needed to treat was 23. However, patients undergoing PCI received prior fibrinolysis, and PCI was performed with a delay of 2-8 days after the index event, which is not representative of current practice. Gibler et al. [44] evaluated the costeffectiveness of DAPT in the setting of STEMI treated with fibrinolysis in CLARITY TIMI-28 and found that clopidogrel therapy was dominant in 35 % of bootstrap simulations and cost less than $50,000 per life year gained (LYG) in 67 % of simulations (Table 1) . However, no analysis is available for the PCI-CLARITY study specifically, and therefore Gibler's study only tangentially elucidates the cost effectiveness of clopidogrel for PCI in this setting.
Similarly, the COMMIT trial demonstrated the efficacy of DAPT with aspirin and clopidogrel in treatment of STEMI [29] . Among the 45,852 patients who were randomized, addition of clopidogrel decreased the combined primary endpoint of death, reinfarction or stroke from 10.1 to 9.2 % in the placebo arm (p = 0.002). A significant reduction in mortality from 8.1 to 7.5 % (p = 0.03) was also noted, representing a 7 % relative risk reduction. A CEA by Berg et al. [45] , based on the CLARITY and COMMIT trials, found that 1 year of DAPT was a dominant strategy in Sweden and France, with cost savings of €111 and €367, respectively, for patients similar to the CLARITY population (Table 1 ). In Germany, the ICER for clopidogrel was €92 per LYG. For patients with a profile and event rates similar to those in the COMMIT study, the incremental cost of treatment with clopidogrel was €538 in Sweden, €798 in Germany and €545 in France, with ICERS of €2,772, €4,144 and €2,786 per LYG, respectively. The authors concluded that the treatment was cost effective in the setting of STEMI. Zhang et al. evaluated the short-and long-term cost effectiveness of clopidogrel plus aspirin versus aspirin alone in medically managed STEMI patients. In short-term findings using patient-level trial data from COMMIT, clopidogrel was a dominant strategy. The lifetime ICER of clopidogrel, extrapolating results from CURE, was $7,806 per LYG [46] . However, the COMMIT trial did not have a significant population of patients undergoing PCI, and therefore these findings are only marginal at best in informing us about the cost effectiveness of clopidogrel in the setting of PCI for the STEMI indication.
As discussed above, another major indication for PCI is stable angina despite guideline-directed medical therapy. In this stable setting, PCI is an elective procedure. The benefits of DAPT with addition of the P2Y12 inhibitors ticlopidine or clopidogrel to aspirin in this group of patients are well documented [47, 48] . The CREDO trial established the currently recommended regimen of long-term treatment with the combination of aspirin and clopidogrel for 12 months after elective PCI [26] . The trial demonstrated a 26.9 % relative reduction in ischaemic events at 1 year (95 % CI 3.9-44.4; p = 0.02).
Subsequently, several CEAs based on the CREDO data were published. Beinart et al. [49] evaluated the long-term cost effectiveness of DAPT compared with aspirin for 1 year. The Framingham Heart Study and the Saskatchewan Health database were used to derive estimates of lost life expectancy due to in-trial events, and in-trial estimates of event rates and costs were used. Using Framinghambased estimates, not including costs beyond the trial period, the ICERs ranged from $3,684 to $4,353. Using Saskatchewan-based estimates, the ICERs ranged from $2,929 to $3,460. Over 97 and 98 % of the bootstrap estimates were below $50,000 per LYG, respectively. The authors concluded that the treatment was highly cost effective. In another analysis, Cowper et al. [50] evaluated the effects of prolonging clopidogrel treatment from 1 month to 1 year. The event rate was based on patients who underwent PCI at Duke Medical Center, with the effect of extended treatment based on the CREDO trial data. For the total sample, the ICER was $15,696 per LYG, ranging from $10,333 per LYG in high-risk patients to $26,568 per LYG in low-risk patients. In a Swedish analysis, Ringborg et al. [51] found that the ICER was €3,022 per LYG and concluded that the three CEAs indicated that long-term treatment with 1 year of clopidogrel after elective PCI is a cost-effective strategy.
On the basis of a meta-analysis combining all three PCIrelated trials of DAPT (the PCI-CLARITY, PCI-CURE and CREDO trials), Berg et al. [52] performed a Markov model-based CEA. The ICERs for Sweden, Germany and France ranged from €4,225 to €7,871 for a treatment duration of 1 year. The authors concluded that this treatment strategy is cost-effective in a wide range of treatment groups.
Prasugrel
Prasugrel is a thienopyridine P2Y12 ADP receptor blocker. Although it is a pro-drug like clopidogrel, it requires fewer steps for conversion to its active form and is a more potent receptor blocker than clopidogrel [53] . In TRITON TIMI-38, prasugrel in combination with aspirin was shown to significantly reduce the rates of ischaemic events in patients undergoing PCI for ACS when compared with the combination of aspirin plus clopidogrel [7, 53] . For ACS patients, the hazard ratio of the primary endpoint of death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke was 0.81 (95 % CI 0.73-0.90; p \ 0.001) for prasugrel vs clopidogrel. Prasugrel was noted to decrease the rates of MI from 9.7 to 7.4 % (p = 0.001) and stent thrombosis from 2.1 to 1.1 % (p = 0.001) compared with clopidogrel, albeit at the expense of increased bleeding rates.
Two published reports evaluated the cost effectiveness of prasugrel in the setting of PCI based on TRITON TIMI-38. In the first study, which used the Saskatchewan Health Database for life expectancy estimates beyond the 14.7 months of trial follow-up, and patient-level outcomes from the trial to derive clinical effect, treatment with prasugrel compared with clopidogrel was projected to decrease costs by $221 and to increase life expectancy by 0.102 years, rendering it an economically dominant strategy [54] . By bootstrap analysis, prasugrel was confirmed as the dominant treatment 79.7 % of the time, while a costeffective ICER of \$50,000 was noted in 99.8 % of repetitions. Prasugrel remained a dominant therapy despite widely varying assumptions during sensitivity analyses. Furthermore, prasugrel remained economically attractive compared with hypothetical generic clopidogrel at a presumed cost of $1 per day, which yielded an ICER of $9,727. The ICER for prasugrel crossed $50,000 when the price difference with clopidogrel reached $7.67.
The second report evaluated the cost effectiveness of prasugrel compared with clopidogrel from the US managed care organization perspective [55] . In this disease-progression model-based study, the current daily costs of $6.08 for clopidogrel and $6.07 for prasugrel were used. Because of the proximity of the availability of generic clopidogrel, a price difference of $3-4 was evaluated in sensitivity analyses. Even at the $3 cost difference, cost savings of $175 per 100 patients were noted with prasugrel. However, at a threshold of a $4 cost difference, prasugrel became the more expensive therapy. Nonetheless, even at that price differential, the cost per LYG was $13,906. The above analyses suggest that prasugrel may be a costeffective alternative to clopidogrel as part of DAPT in patients undergoing PCI for ACS.
Ticagrelor
Ticagrelor is an oral non-thienopyridine inhibitor of the P2Y12 ADP receptor. It provides more rapid and efficacious platelet inhibition than clopidogrel [56] . In the PLATO trial, carried out in the setting of ACS, ticagrelor was shown to reduce the composite primary endpoint of death from vascular causes, MI or stroke from 11.7 to 9.8 % when compared with clopidogrel (HR 0.84; 95 % CI 0.77-0.92; p \ 0.001) [8] . Moreover, ticagrelor reduced the risk of death from vascular causes from 5.1 to 4.0 % (p = 0.001), corresponding to an absolute risk reduction of 1.1 %. This was achieved with no significant difference in the rate of major bleeding, albeit with an increase in non-CABG-related bleeding from 3.8 % with clopidogrel to 4.5 % (p = 0.03). Ticagrelor is now approved for use in patients with ACS undergoing PCI.
The cost effectiveness of ticagrelor, based on data from the PLATO study, was published by Nikolic et al. [57] . Over a lifetime, the ICER was €2,753 per QALY gained. In a 2011 evaluation of ticagrelor by the National Institute for Health and Care Excellence (NICE) of the British National Health Service, the committee noted that all ICERs for ticagrelor were below £5,400 in the manufacturer's submission, but that because of some inherent flaws in the model used for the calculation, more plausible ICERs were £7,897 per QALY gained for all ACS, £8,872 per QALY gained for STEMI, £7,215 per QALY gained for NSTEMI and £9,131 per QALY gained for unstable angina, based on their Evidence Review Group's sensitivity analyses [58] . Ticagrelor therefore gained NICE approval and was deemed cost effective. Thus, it appears that although robust peer-reviewed evidence is still lacking for ticagrelor, it is likely to be a cost-effective approach to treatment for patients undergoing PCI in the setting of ACS.
Glycoprotein IIb/IIIa Inhibitors
GP IIb/IIIa inhibitors interfere with the final common pathway in platelet aggregation. There are three agents currently available in the USA. Abciximab is a monoclonal chimeric antibody that binds the GP IIb/IIIa receptor noncompetitively but irreversibly, while the small-molecule agents eptifibatide and tirofiban are competitive GP IIb/IIIa inhibitors with reversible binding. The biologic half-life of abciximab is approximately 12-24 h, while eptifibatide and tirofiban show recovery of platelet aggregation after 4 h [4] . As previously discussed, these agents have shown efficacy in the setting of PCI for stable CAD and ACS, but most pivotal trials evaluating their clinical effectiveness were carried out in the era before routine stenting during PCI and routine DAPT, and with heparin as the predominant anticoagulation therapy [59] [60] [61] [62] [63] [64] [65] . In more recent trials, addition of GP IIb/IIIa inhibitors to anticoagulation therapy (e.g. bivalirudin) on a background of pretreatment with clopidogrel showed no benefit, with the possible exception of high-risk ACS [10, [66] [67] [68] [69] . For example, in a 2009 meta-analysis of 16 trials of GP IIb/IIIa inhibitors including 10,085 patients with STEMI, De Luca found they did not reduce 30-day mortality (2.8 vs 2.9 %; p = 0.75) or reinfarction (1.5 vs 1.9 %; p = 0.22), but they did significantly increase major bleeding complications (4.1 vs 2.7 %; p = 0.0004) [70] . A significant relationship between an increased patient risk profile and potential mortality benefit was observed.
The current ACC/AHA guidelines for PCI therefore reflect the paucity of clearly demonstrated benefit of GP IIb/IIIa inhibitors in the current PCI era [2] . Recommendations vary depending on the clinical setting, level of patient risk and anticoagulant used: in the setting of STEMI, administration of these agents is a class IIa indication (albeit with evidence level C [consensus] in patients pretreated with clopidogrel); in high-risk troponin-positive non-ST-elevation ACS patients who are not adequately pretreated with clopidogrel and not treated with bivalirudin, GP IIb/IIIa inhibitors have a class I indication; in patients undergoing elective PCI, these agents have a class IIa or IIb indication without and with pretreatment with clopidogrel, respectively. There are no explicit recommendations for use of these agents in patients treated with bivalirudin as an anticoagulant. However, they are used provisionally in this setting.
Although multiple evaluations of cost effectiveness of abciximab, eptifibatide and tirofiban have been published, these analyses are based on the older studies of clinical effectiveness [71] [72] [73] [74] [75] [76] . From the positive results of these studies, it appears that in aggregate, use of GP IIb/IIIa inhibitors in addition to heparin alone without routine background DAPT is cost effective. However, it is unclear whether the use of these agents would be cost effective in the current era of PCI with routine stenting, DAPT and frequent use of bivalirudin as an anticoagulant. For example, when comparing strategies for patients undergoing PCI with stenting based on REPLACE 2, Cohen et al. [77] and Summer et al. [78] found that bivalirudin with provisional GP IIb/IIIa inhibitor use dominated heparin with routine GP IIb/IIIa inhibitor use [79] . Also, in the setting of STEMI, Schwenkglenks evaluated the cost effectiveness of bivalirudin with provisional GP IIb/IIIa inhibitor use versus heparin with routine GP IIb/IIIa inhibitor use on a background of aspirin and clopidogrel pretreatment [80] . The analysis, based on the results of the HORIZONS AMI trial, found that in 99.2 % of simulations, bivalirudin with provisional GP IIb/IIIa inhibitor use had ICERs below £20,000 per QALY gained. Similarly, evaluation of this strategy in patients with non-ST-elevation ACS, based on the results of the ACUITY trial, found that the ICER was £9,906 per QALY gained; with 71.2 % of simulations, the ICER remained under £20,000 [81] . The results of these analyses suggest that use of GP IIb/IIIa inhibitors as provisional agents adjunctively with bivalirudin is a more cost-effective strategy than routine use with heparin.
Platelet Function Testing and Genetics
Clinical evaluation of still controversial strategies, including on-treatment platelet reactivity-guided and genetic testing-guided DAPT, is currently ongoing. While there has been a preliminary CEA of genotype-driven therapy, more definitive analyses of such strategies will need to be conducted if a therapeutic benefit of platelet reactivity testing or genotype-guided DAPT is shown [82] .
Conclusions
Overall, the use of DAPT with aspirin and a P2Y12 inhibitor in patients undergoing PCI improves ischaemic outcomes and appears to be cost effective. The available studies suggest that newer agents such as prasugrel and ticagrelor are cost-effective alternatives to clopidogrel in the setting of ACS. However, no direct comparison between prasugrel and ticagrelor is available. The use of GP IIb/IIIa inhibitors is changing in the current PCI era, but they appear to be cost effective as provisional agents used with bivalirudin or when used with heparin in patients not treated with up-front DAPT. There is a paucity of evidence for the cost effectiveness of routine GP IIb/IIIa inhibitor use with heparin on the background of P2Y12 inhibitor loading, especially in patients undergoing PCI for stable CAD or low-risk ACS.
The cost effectiveness of platelet function and genetic testing-guided DAPT will need to be evaluated if a therapeutic benefit of such strategies is demonstrated. Additionally, the optimal duration of DAPT has not yet been definitively established, and studies are ongoing to evaluate regimens as short as 6 months. Should such approaches prove to be clinically acceptable, the cost-effective attractiveness of such strategies would strengthen the argument for their implementation. In the era of acute societal awareness of the limited healthcare resources available to treat an unlimited number of ailments, CEAs continue to be of utmost importance in evaluation of novel therapies, especially in the rapidly evolving field of interventional cardiology.
